Last Updated: 10 December 2024
AQEMIA, a pioneering techbio company leveraging atomic-scale physics and generative AI to design innovative medicines, has announced two major milestones: surpassing $100 million in cumulative funding and launching a global expansion with a new office in London, UK.
The recent $38 million funding round, led by Cathay Innovation, brings AQEMIA’s total funding to over $100 million. This round follows less than a year after the previous one, underscoring the rapid validation of AQEMIA’s drug discovery platform.
Exceptional results in preclinical programs and pharmaceutical partnerships, particularly in oncology, highlight the platform’s potential.
AQEMIA’s recent funding and global expansion highlight its impact on the healthcare and techbio industries. By combining generative AI with quantum mechanics, AQEMIA is pioneering innovative approaches to drug discovery.
"This is a transformative moment for AQEMIA. Less than a year after our last round, this successful fundraising and the opening of our new London office mark significant strides toward our ambition to accelerate the discovery of new medicines on a global scale. Partnering with Cathay Innovation brings international expertise, particularly in the US and Asia, reinforcing our vision and mission. With this momentum, we are poised to advance to clinical trials, bringing us closer to delivering life-changing treatments to patients in need."
Maximilien Levesque, PhD, CEO and co-founder of AQEMIA
AQEMIA will allocate the funds toward advancing its drug discovery platform, preparing for clinical trials, and supporting global recruitment efforts. The company also aims to continue its internal preclinical programs with a strong focus on oncology.
They plan to establish itself as a leader in generative AI for drug discovery. The funds will accelerate the development of innovative and safe small-molecule drugs, as well as expand operations globally, starting with a new office in London.
Founded by Maximilien Levesque, PhD, and Emmanuelle Martiano Rolland, AQEMIA is a next-generation techbio company revolutionizing drug discovery.
By teaching quantum-inspired, atomic-scale physics to generative AI, AQEMIA designs novel drug candidates without relying on experimental data.
This groundbreaking approach allows for the creation of molecules beyond existing frameworks, tackling critical diseases with unprecedented efficiency.
Cathay Innovation leads this funding round, joined by prominent investors including Wendel, Bpifrance Large Venture, Eurazeo, and Elaia.
Earlier this year, AQEMIA boosted its Series A funding to €60 million to accelerate work on its proprietary therapeutic pipeline.
With this latest $38 million, AQEMIA has reached $100 million in total funding, underscoring its rapid growth and strong position in the global techbio landscape.
"AQEMIA embodies the future of drug discovery, combining the power of AI with quantum mechanics. Fueled by Maximilien and Emmanuelle, the company’s vision is one that is fully aligned with Cathay Innovation’s DNA, as it aims to profoundly transform the molecule research and pharmaceutical industry as a whole. Our partnership goes beyond capital support; we are putting to good use our experience in scaling AI-driven companies all over the world, particularly across US and Asia, as AQEMIA accelerates its path to the clinic and expands its global impact."
Jacky Abitbol, partner at Cathay Innovation
